DRAGARWQ5,301.00

Dr Agarwals Eye Hospital Limited

· Pharma & Health
₹ CrorePeersKMCSHILKOVAILOTUSEYEGPTHEALTHGKSLSHALBYINDRAMEDCOARTEMISMED
Comp Set
In ₹ Crore except Per Share
Latest Annual
DRAGARWQ
FY26
KMCSHIL
FY24
KOVAI
FY20
LOTUSEYE
FY26
Peer
Median
Valuation — at last close
P/E36.06×74.09×73.46×2812.50×74.09× -51%
P/B3.89×3.89×
EV/EBITDA72.00×72.00×
Market Cap₹234 Cr₹234 Cr
Growth
Revenue CAGR 3Y20.68%19.96%4.52%12.24% +69%
Revenue CAGR 5Y22.59%10.66%10.66% +112%
Net Income CAGR 3Y23.83%33.46%-72.98%-19.76% +221%
Revenue YoY (latest Q)26.19%26.19%
Net Income YoY (latest Q)12.65%12.65%
Profitability
EBITDA Margin30.86%26.75%23.61%6.30%23.61% +31%
Net Income Margin14.89%17.15%13.29%0.15%13.29% +12%
Return on Common Equity20.24%21.94%0.13%11.04% +83%
Return on Capital Employed15.21%10.47%-0.50%4.99% +205%
Return on Assets9.15%8.54%0.10%4.32% +112%
Credit & Quality
Total Debt/Equity0.24×1.18×0.19×0.68× -65%
Interest Coverage8.39×32.79×7.93×-0.43×7.93× +6%
Scale — latest FY
Revenue / Total Income₹471 Cr₹177 Cr₹712 Cr₹53.7 Cr₹177 Cr +166%
Net Income₹70.1 Cr₹30.4 Cr₹94.6 Cr₹0.1 Cr₹30.4 Cr +131%
Total Assets₹766 Cr₹1,107 Cr₹82.6 Cr₹595 Cr +29%
EPS₹147.02₹1.86₹86.44₹0.04₹1.86 +7804%
Book Value per Share₹28.92₹28.92
◆ best value in the comp set per metric · Δ = subject vs median of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 85%.